Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Established in 1998, the company has built significant expertise in engineering peptides to enhance biological activity, stability, and duration, enabling the development of next-generation therapeutics. Zealand Pharma focuses its research and development efforts on three primary therapeutic areas: obesity and obesity-related comorbidities, rare diseases, and chronic inflammation. The company's pipeline includes a diverse range of clinical and pre-clinical candidates, targeting conditions such as obesity, type 2 diabetes, congenital hyperinsulinism, short bowel syndrome, and various autoimmune and inflammatory disorders. Notably, Zealand Pharma has successfully brought peptide-based drugs to market, validating its platform and strengthening its industry presence. With a strong emphasis on addressing unmet medical needs, the company pursues global development and commercialization partnerships to expand access to its therapies. Zealand Pharma plays a notable role in advancing peptide research within the biotechnology sector, supporting innovation and the development of novel treatments for complex, underserved medical conditions.